Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca: Court denies Teva motion on Pulmicort Respules

AstraZeneca: Court denies Teva motion on Pulmicort Respules

26th September 2008

AstraZeneca has announced that a court has denied the motion from Teva for summary judgement in the patent litigation for Pulmicort Respules (budesonide inhalation suspension).

Teva has called for a judgement of no infringement in this case, but this was denied by the US District Court for the District of New Jersey.

Furthermore, the court said a trial date will be scheduled shortly and is likely to occur in January 2009.

AstraZeneca said it has remained focused on its preparation for this trial and expressed confidence in the robustness of its intellectual property protecting this compound.

“In October of 2005, AstraZeneca announced that it had filed a lawsuit in the US District Court for the District of New Jersey against Ivax Pharmaceuticals – now known as Teva Pharmaceutical Industries – for patent infringement,” the company added.

It noted this lawsuit followed a new drug application to market a generic form of Pulmicort Respules before its patent expired in 2018.

AstraZeneca also said the US Food and Drug Administration has not approved a generic formulation of the compound and has not yet responded to the company’s citizen petition filed in 2006.

Earlier this week, AstraZeneca and Targacept announced inconclusive top-line results from their phase IIb study of AZD3480 in patients with Alzheimer’s disease.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.